

162

GP164/3
#4

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to the Assistant Commissioner for Patents, Washington DC 20231.

Ivonne Escudero
Ivonne Escudero

July 14, 1998
Date

Patents

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of: B.A. Ozenberger et al.

Group Art Unit.: 1643

Serial No.: 09/060,609

Examiner:

Docket No.: AHP-98126

Filed: April 15, 1998

For: "β-Amyloid Peptide-Binding Proteins and Polynucleotides
Encoding the Same"

July 14, 1998

Assistant Commissioner for Patents
Washington DC 20231

RECEIVED
98 JUL 21 PM 12:47
GROUP 180

Information Disclosure Statement

S I R:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the following documents which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies of the documents set forth below and listed on the attached Form PTO-1449 are provided herewith.

1. J. Biol. Chem., "Modulation of GDP Release from Transducin by the Conserved Glu¹³⁴Arg¹³⁵ Sequence in Rhodopsin", S. Acharya et al., 271, No. 41, (Oct. 1996) pp. 25406-411;

2. J. Mol. Biol., "Basic Local Alignment Search Tool", S.F. Altschul et al., (1990) 215, pp. 403-410;

3. Lett. Nature, "Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor", F. Revah et al., 353, (Oct. 1991), pp. 846- ;

4. Nature, "RAGE and Amyloid-β-peptide neurotoxicity in Alzheimer's disease", Shi Du Yan et al., 382, (Aug. 1996) pp. 685-691;

5. Nature, "Scavenger receptor-mediated adhesion of microglia to β -amyloid fibrils", J. El Khoury et al., 382 (Aug. 1996), pp. 716-719;
6. Nature, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease", 349 (Feb. 1991), pp. 704-706;
7. Nature Genetics, "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β -amyloid precursor protein gene", L. Hendriks et al., 1 (June 1992), pp. 218-221.
8. Neurobiology of Aging, "A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs", J.S. Jacobsen et al., 12, (1991) pp. 575-583.
9. J. Biol. Chem., "The release of Alzheimer's disease β amyloid peptide is reduced by phorbol treatment", J.S. Jacobsen et al., 269, No. 11 (March 1994), pp. 8376-8382.
10. Mol. Cell. Biol., "Effects of expression of mammalian $G\alpha$ and hybrid mammalian yeast $G\alpha$ proteins on the yeast pheromone response signal transduction pathway", Yoon-Se Kang et al., 10, No. 6 (June 1990), pp. 2582-2590.
11. Nat. Genetics, "The Alzheimer's $A\beta$ peptide induces neurodegeneration and apoptotic cell death in transgenic mice", 9, (Jan. 1995), pp.21-30.
12. A. Neuropathol., "Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ", H. Lassman et al., 89 (Springer-Verlag 1995), pp. 35-41.
13. Science, "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", 243, (June 1990), pp. 1124-1126.
14. Neurobiology, "Apoptosis is induced by β -amyloid in cultured central nervous system neurons", D.T. Loo et al., 90, (Sept. 1993), pp. 7951-7955.
15. Med. Sciences, "Reversible in vitro growth of Alzheimer disease β -amyloid plaques by deposition of labeled amyloid peptide", J.E. Maggio et al., 89 (June 1992), pp. 5462-5466.
16. Nat. Genetics, "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β -amyloid", M. Mullan et al., 1 (Aug. 1992), pp. 345-347.
17. Sci., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease", J. Murrell et al., 254 (Oct. 1991), pp. 97-99.
18. Lett. Nat., "Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G_o ", I. Nishimoto et al., 362 (March 1993), pp. 75-79.
19. Nat. Medicine, "Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP

mutations linked to familial Alzheimer's disease", D. Scheuner et al., 2 No. 8 (Aug. 1996), pp. 864-70.

20. Neurosci., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", D.J. Selkoe, 275 (Jan. 1997), pp. 630-31.

21. J. Neurosci., "Voltage-gated K⁺ channel β subunits: Expression and distribution of Kv β 1 and Kv β 2 in adult rat brain", K.J. Rhodes et al., 16 (Aug. 1996), pp. 4846-60.

22. Mol. Endo., "Functional interaction of ligands and receptors of the hematopoietic superfamily in yeast", B.A. Ozenberger et al., 9 No. 10 (1995), pp. 1321-29.

23. Exp. Neurology, "Evidence of apoptotic cell death in Alzheimer's disease", G. Smale et al., 133 (1995), pp. 225-30.

24. Sci., "Amyloid β protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus", (Jan. 1987), pp. 880-84.

25. Proc. Natl. Acad. Sci., "Detection of conserved segments in proteins: Iterative scanning of sequence databases with alignment blocks", R.L. Tatusov et al., 91 (Dec. 1994), pp. 12091-95.

26. Cell, "The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases", J. Wade Harper et al., 75 (Nov. 1993), pp. 805-16.

27. Elsevier Sci., "Ultrastructural analysis of β -amyloid-induced apoptosis in cultured hippocampal neurons", J.A. Watt et al., 661 (1994), pp. 147-156.

28. Sci., "G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP", T. Yamatsuji et al., 272 (May 1996), pp. 1349-52.


29. Nature, "An intracellular protein that binds amyloid- β peptide and mediates neurotoxicity in Alzheimer's disease", Shi Du Yan et al., 389 (Oct. 1997), pp. 689-

The present Information Disclosure Statement is being filed no later than three months from the application's filing date and/or before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1,17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Andrea Walsh", written over a horizontal line.

Andrea C. Walsh
Their Attorney
Reg. No. 34,988
(973) 683-2169

American Home Products
Patent Department, 2B
One Campus Drive
Parsippany, NJ 07054